Blacksmith Medicines to Present Preclinical Oncology Data at 8th DDR Inhibitors Summit
Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, announced today that it will present preclinical data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the 8th DDR Inhibitors Summit taking place January 28th – […]